SEC Form 4 · accession 0001179110-16-024408
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philip S Low
Officer — Chief Science Officer · Director
Period of report
May 10, 2016
Accepted (ET)
May 12, 2016 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 10, 2016 | G | 11,566 | $0.00 | D | 206,606 | D | |
| Common StockF1 | May 10, 2016 | P | 11,375 | $3.52 | A | 217,981 | D | |
| Common Stock | holding | — | — | — | 193,318 | I | By spouse trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the purchase of 11,375 shares in multiple transactions, ranging in price from $3.46 to $3.56 per share, resulting in a weighted average purchase price per share of $3.52. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price within the range.